"Effect of vitamin E in preventing kidney problems in thalassemia patients"

Evaluation of the effect of vitamin E on prevention of acute kidney injuray and Fanconi syndrome caused by iron chelators in thalassemia patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221111056466N1

Enrollment

Registered

2022-12-19

Start date

2022-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Thalassemia. Condition 2: Acute Kidney Injury. Condition 3: Fanconi syndrome. Condition 4: Abnormal Kidney function. Beta thalassemia Acute kidney failure with tubular necrosis Disorders of amino-acid transport Abnormal results of kidney function studies

Interventions

Intervention 1: Intervention group: In addition to the standard treatment, this group receives a daily iron chelator called Jedneo 360 mg tablet with the generic name Defrasirox of Swiss company NOVAR

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with thalassemia are covered by Amir Kabir Arak Hospital

Exclusion criteria

Exclusion criteria: All patients who are covered by Amirkabir Hospital but do not consent to participate in the study.

Design outcomes

Primary

Measure	Time frame
Creatinine level. Timepoint: It will be checked on the first day of the study and 48 hours and 7 days after the start of the study. Method of measurement: blood samples.;Glomerular filtration rate. Timepoint: It will be checked on the first day of the study and 48 hours and 7 days after the start of the study. Method of measurement: blood sample.;Blood phosphorus level. Timepoint: It is checked on the first day of the study and 30 days after the start of the study. Method of measurement: blood sample.;Urine glucose level. Timepoint: It is checked on the first day of the study and 30 days after the start of the study. Method of measurement: urine sample.;Venous blood gas level. Timepoint: It is checked on the first day of the study and 30 days after the start of the study. Method of measurement: blood sample.;The ratio of blood urea nitrogen to creatinine. Timepoint: It is checked on the first day of the study and 30 days after the start of the study. Method of measurement: blood sample.	—

Measure

Time frame

Creatinine level. Timepoint: It will be checked on the first day of the study and 48 hours and 7 days after the start of the study. Method of measurement: blood samples.;Glomerular filtration rate. Timepoint: It will be checked on the first day of the study and 48 hours and 7 days after the start of the study. Method of measurement: blood sample.;Blood phosphorus level. Timepoint: It is checked on the first day of the study and 30 days after the start of the study. Method of measurement: blood sample.;Urine glucose level. Timepoint: It is checked on the first day of the study and 30 days after the start of the study. Method of measurement: urine sample.;Venous blood gas level. Timepoint: It is checked on the first day of the study and 30 days after the start of the study. Method of measurement: blood sample.;The ratio of blood urea nitrogen to creatinine. Timepoint: It is checked on the first day of the study and 30 days after the start of the study. Method of measurement: blood sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Moradigoudarzi

Arak University of Medical Sciences

moradi_goudarzi@yahoo.com+98 66 4230 8306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026